Laboratoires Servier
Laboratoires Servier, a prominent French pharmaceutical company, is headquartered in Suresnes, France. Founded in 1954, Servier has established itself as a key player in the global healthcare industry, with a strong presence in Europe, Asia, and Africa. The company focuses on innovative treatments in various therapeutic areas, including cardiology, diabetes, oncology, and neurology. Servier is renowned for its commitment to research and development, investing significantly in new drug discovery and development. Its core products, such as the antihypertensive medication Perindopril, exemplify the company's dedication to improving patient outcomes through unique formulations and comprehensive treatment solutions. With a robust portfolio and a reputation for quality, Laboratoires Servier continues to strengthen its market position, achieving notable milestones in both innovation and patient care.
DitchCarbon Score
How does Laboratoires Servier's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Laboratoires Servier's score of 29 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Laboratoires Servier's reported carbon emissions
In 2024, Laboratoires Servier reported total greenhouse gas emissions of approximately 79,432,000 kg CO2e for Scope 1 and about 33,048,000 kg CO2e for Scope 2, resulting in a combined total of around 102,893,000 kg CO2e. This marks a slight increase from 2023, where emissions were approximately 71,457,000 kg CO2e for Scope 1 and 36,432,000 kg CO2e for Scope 2, totalling about 107,889,000 kg CO2e. Laboratoires Servier has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 emissions by 25% by 2030 from a 2016 baseline. Additionally, they plan to cut Scope 3 emissions from capital goods, waste generated in operations, business travel, and employee commuting by 25%, and from downstream transportation and distribution by 21%, all by 2030. Furthermore, Servier has committed to ensuring that key suppliers, representing 52% of emissions from purchased goods and services, will establish science-based targets for Scope 1 and 2 emissions by 2024. The company’s emissions data and reduction targets are aligned with the Science Based Targets initiative (SBTi), reflecting their commitment to climate action within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 62,044,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 54,578,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Laboratoires Servier is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
